Wall Street Zen Downgrades Tilray Brands to Sell Amid Analyst Revisions

Tilray Brands (NASDAQ: TLRY) has received a downgrade from a “hold” rating to a “sell” rating by analysts at Wall Street Zen, according to a report published on January 20, 2024. This decision reflects a broader trend among various research firms reassessing their outlook on the cannabis company, which has seen its stock performance fluctuate dramatically in recent months.

Several notable changes in ratings have emerged. Roth MKM revised its price target for Tilray from $20.00 to $10.00, maintaining a “neutral” stance on the stock. Zacks Research upgraded its rating from “strong sell” to “hold” just days later, on January 21. In contrast, Weiss Ratings reaffirmed a “sell (d-)” rating on the shares, highlighting ongoing concerns about the company’s financial health.

Analyst Ratings Overview

The shifting analyst sentiment is not limited to Wall Street Zen. Canaccord Genuity Group initiated coverage with a “hold” rating on January 27, while ATB Cormark Capital Markets upgraded its previous “strong sell” rating to a “hold” on December 10, 2023. Overall, analysts have mixed views on Tilray Brands: one has assigned a “buy” rating, six analysts have a “hold” rating, and one has a “sell” rating. The stock currently holds an average rating of “hold” with a target price of $13.33, according to MarketBeat.

Tilray Brands opened trading at $7.51 on January 19, 2024, showcasing a significant decline from its one-year high of $23.20. The company’s market capitalization stands at approximately $874.99 million, with a price-to-earnings ratio of -0.34 and a beta of 2.02. The stock has experienced a one-year low of $3.51, indicating substantial volatility.

Recent Financial Performance

Tilray Brands reported its latest earnings results on January 8, 2024. The company posted a loss of ($0.41) earnings per share, which was significantly below analysts’ consensus estimate of ($0.14), missing projections by ($0.27). The company had a negative net margin of 251.69% and a negative return on equity of 6.35%. Revenue for the quarter reached $217.51 million, slightly exceeding analysts’ expectations of $211.15 million. In the same period last year, Tilray had posted earnings of ($0.03) per share, indicating a downward trend in profitability.

Analysts anticipate that Tilray Brands will post earnings of -0.20 per share for the current fiscal year, reflecting ongoing challenges in the cannabis market.

Institutional Investor Activity

Recent activity among institutional investors indicates a mixed outlook for Tilray Brands. Tidal Investments LLC increased its holdings by 15.0% during the second quarter, owning a total of 28,971,835 shares valued at approximately $12 million after acquiring an additional 3,776,410 shares. Meanwhile, Millennium Management LLC boosted its holdings by 281.0% in the third quarter, acquiring 4,942,319 shares worth about $8.55 million.

Other investors, including MIRAE ASSET GLOBAL ETFs HOLDINGS Ltd. and Ausdal Financial Partners Inc., have also taken positions in Tilray, demonstrating varying levels of confidence in the company’s future. Currently, around 9.35% of Tilray’s stock is owned by hedge funds and other institutional investors.

Tilray Brands, Inc. is a prominent player in the global cannabis industry, focusing on the cultivation, production, distribution, and sale of both cannabis and cannabinoid-based products. The company’s diverse portfolio includes medical cannabis, adult-use recreational products, and wellness offerings. Through advanced cultivation facilities and stringent quality control systems, Tilray aims to meet the evolving needs of both patients and consumers.

As the cannabis market continues to evolve, Tilray Brands will need to navigate these analyst downgrades and operational challenges to regain investor confidence.